Assessment of the Progression of Vertical Semicircular Canal Dysfunction and Increased Vestibular Endolymphatic Hydrops in Patients With Early-Stage Ménière Disease.
Journal
JAMA otolaryngology-- head & neck surgery
ISSN: 2168-619X
Titre abrégé: JAMA Otolaryngol Head Neck Surg
Pays: United States
ID NLM: 101589542
Informations de publication
Date de publication:
01 09 2020
01 09 2020
Historique:
pubmed:
10
7
2020
medline:
2
3
2021
entrez:
10
7
2020
Statut:
ppublish
Résumé
Vertical semicircular canals and endolymphatic hydrops play important roles in the pathophysiological mechanisms of Ménière disease. However, their characteristics and associations with disease progression during medical treatment have not been determined. To examine the function of both the horizontal and vertical semicircular canals in patients with Ménière disease and to evaluate the change in endolymphatic hydrops volume during medical treatment, including treatment with diuretic therapy, over a 2-year period. This prospective longitudinal observational cohort study included 55 patients with definite unilateral Ménière disease and was performed in a tertiary care hospital in Japan. Participants were enrolled between April 1, 2017, and January 31, 2018, and those with vestibular migraine were excluded. All participants received education regarding diet and lifestyle modifications and treatment with betahistine mesylate (36 mg daily) and/or an osmotic diuretic (42-63 mg daily). Patients were followed up for vertigo and hearing evaluations at least once per month for more than 12 months and were instructed to record episodes of vertigo in a self-check diary. Audiometry was performed monthly, video head impulse testing and caloric testing were performed every 4 months, and magnetic resonance imaging was conducted annually. Data were analyzed from May 15, 2017, to January 31, 2020. Neurootological testing to evaluate vestibuloocular reflex gain over time, magnetic resonance imaging to evaluate the change in endolymphatic hydrops volume over time, and monthly vertigo and hearing evaluations for more than 12 months. Among 55 participants with definite Ménière disease, 32 patients (58.2%) were female, and the mean (SD) age was 59.0 (15.1) years. The median disease duration was 2 years (interquartile range, 0-4 years), with 43 patients (78.2%) having an early stage (ie, disease duration ≤4 years) of Ménière disease. Over the 2-year study period, the vestibuloocular reflex gain decreased from 0.76 to 0.56 in the superior semicircular canals, for a difference of 0.20 (95% CI, 0.14-0.26) and from 0.68 to 0.50 in the posterior semicircular canals, for a difference of 0.18 (95% CI, 0.14-0.22). The maximum slow-phase velocity and vestibuloocular reflex gain in the horizontal semicircular canals were maintained. The volume ratio of vestibular endolymphatic hydrops increased from 19.7% to 23.3%, for a difference of 3.6% (95% CI, 1.4%-5.8%). The frequency of vertiginous episodes decreased, and the hearing level over the study period worsened from 40.9 dB to 44.5 dB, for a difference of 3.5 dB (95% CI, 0.7-6.4 dB). In this study, during a 2-year period of medical treatment among patients with Ménière disease, vestibuloocular reflex gain decreased in the vertical semicircular canals but was maintained in the horizontal semicircular canals; the endolymphatic hydrops volume ratio increased, and the frequency of vertiginous episodes decreased. These findings describe the pathological progression of chronic Ménière disease and expand the understanding of its pathophysiological characteristics during the early stage of disease.
Identifiants
pubmed: 32644132
pii: 2767835
doi: 10.1001/jamaoto.2020.1496
pmc: PMC7349148
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
789-800Commentaires et corrections
Type : ErratumIn
Références
Magn Reson Med Sci. 2013 Mar 25;12(1):63-8
pubmed: 23474961
Otol Neurotol. 2002 May;23(3):372-7
pubmed: 11981398
Magn Reson Med Sci. 2012;11(3):213-9
pubmed: 23037568
Laryngoscope. 2019 Jul;129(7):1660-1666
pubmed: 30515842
Otol Neurotol. 2011 Sep;32(7):1152-7
pubmed: 21817938
PLoS One. 2017 Nov 30;12(11):e0188301
pubmed: 29190293
Proc R Soc Med. 1938 Sep;31(11):1317-36
pubmed: 19991672
Acta Otolaryngol. 2014 Nov;134(11):1128-33
pubmed: 25315912
PLoS One. 2011 Jan 26;6(1):e16497
pubmed: 21298075
Otolaryngol Head Neck Surg. 1995 Sep;113(3):181-5
pubmed: 7675476
J Int Adv Otol. 2019 Apr;15(1):112-117
pubmed: 31058600
J Neurosci Res. 2010 May 1;88(6):1262-72
pubmed: 19908248
Otol Neurotol. 2003 Nov;24(6):913-7
pubmed: 14600474
Acta Otolaryngol. 2015 Sep;135(9):859-65
pubmed: 26087818
Otol Neurotol. 2012 Jul;33(5):832-9
pubmed: 22699991
Acta Otolaryngol. 2010 Jun;130(6):644-51
pubmed: 20001444
Headache. 1997 Nov-Dec;37(10):615-21
pubmed: 9439080
J Neurol. 2019 Jun 20;:
pubmed: 31222419
JAMA Otolaryngol Head Neck Surg. 2019 Jun 1;145(6):583-585
pubmed: 30998827
Laryngoscope Investig Otolaryngol. 2017 Oct 31;2(6):344-350
pubmed: 29299506
Eur Ann Otorhinolaryngol Head Neck Dis. 2018 Jun;135(3):167-169
pubmed: 29274769